 |
 |
|
|
Prostate Cancer Home |
Survival Rates |
Medical Staff |
Nurse Coordinator |
Diagnostics |
Treatment & Technology |
Case Conferences |
Clinical Trials |
Support Groups |
Cancer Education |
Patient Stories
Winning Against Prostate Cancer
For more than a decade, Hoag Cancer Center has been the number one provider for urologic malignancies in Orange County, including the highest volume of prostate cancer patients. With a multidisciplinary approach that includes prevention, early detection, the use of standard and promising new therapies, participation in laboratory and clinical research, and extensive complementary care, the team at Hoag Cancer Center provides prostate cancer patients with every diagnostic and therapeutic advantage.
Hoag’s comprehensive site-specific prostate cancer program provides:
Back to Top
Survival Rates
The superior care provided to Hoag prostate cancer patients is most clearly illustrated by having a relative five-year survival rate of 100 percent since the early 1990s. As shown in the figure below.
Hoag was a leader in the use of prostate specific antigen to screen for prostate cancer. This is one of the reasons that more than 90 percent of Hoag prostate cancer patients have only localized disease at the time a diagnosis of prostate cancer is made.
Back to Top
Medical Staff Expertise
Hoag’s expert team of board-certified urologic cancer surgeons, robotic surgeons, radiation oncologists and medical oncologists provide the latest in state-of-the-art surgical procedures and treatment options for patients with prostate cancer.
Additionally, Hoag’s expert medical staff is complemented by its highly trained team of certified oncology nurses. Dedicated to delivering patient-centered care, Hoag’s nursing staff ranks among the nation’s top nurses, as validated by Hoag’s designation as a Magnet™ hospital by the American Nurses Credentialing Center.
Hoag-Affiliated Prostate Cancer Experts
Associate Medical Director, Urologic Cancer
Jeffrey Yoshida, M.D., is the Associate Medical Director of Urologic Oncology at Hoag Cancer Center. For more information, please select from any of the following: Dr. Yoshida’s bio, contact information, or news release about his appointment as associate medical director.
Physician Expertise
Obtaining your cancer care from a medical team that treats a high volume of patients with your specific cancer type has its advantages – namely, successful patient outcomes. Studies show that physicians who treat large numbers of patients with a specific disease achieve better patient outcomes. Hoag physicians treat and manage more prostate cancer patients than any other facility in Orange County.
Hoag’s expert medical team and long tradition of high survival rates are just two reasons why patients diagnosed at Hoag remain at Hoag for treatment.
Back to Top
Urologic Cancer Nurse Coordinator
The Urologic Cancer Nurse Coordinator is a unique asset to Hoag’s comprehensive prostate cancer program. The coordinator serves an important role as facilitator and guide for patients, answering questions and providing support through each phase of treatment.
Hoag’s urologic cancer nurse coordinator provides:
- Emotional support and guidance for the newly diagnosed patient and family
- Education for patients and family members about prostate cancer
- Information about community resources and Hoag support services
- Help in coordinating the multidisciplinary care plan
- Assistance in navigating the healthcare system during and after treatment
Nancy Raymon, R.N., M.N., graduated with a bachelor of science degree in nursing from Arizona State University in 1972. She completed her master’s degree in nursing at UCLA in 1976 with a clinical specialization in oncology nursing. Nancy has worked at Hoag Cancer Center since 2000, and assumed the role of Urologic Cancer Nurse Coordinator in April 2008.
According to Nancy, “Patients have been the highlight of my career. It is an honor to enter someone’s life at a time of crisis. The rewards are great for those of us who are fortunate enough to be in a position to educate, support and guide patients through the cancer experience. The greatest reward for me is seeing a patient progress from a position of uncertainty and doubt to one of confidence and hope. Facilitating that transition is the most important part of my role.”
To speak with Urologic Cancer Nurse Coordinator Nancy Raymon, R.N., M.N., please call 949/764-1804.
Back to Top
Diagnostics
The most important screening test for prostate cancer is the prostate specific antigen (PSA). Prostatic ultrasound guided biopsy is used to diagnose prostate cancer. Serum PSA levels are used as a tumor marker to monitor the disease after surgery and/or radiation therapy.
Hoag’s state-of-the-art diagnostic services give patients convenient access to a full spectrum of technologies that enable doctors to pinpoint the nature and extent of the disease – and the best treatment plan for each individual patient.
Hoag’s sophisticated imaging technology and expert radiologists provide an essential component of service. Detailed images of the tumor site, contours and dimensions help physicians determine an accurate diagnosis and develop an effective treatment plan.
Hoag offers leading-edge, minimally invasive technology that allows physicians to evaluate the presence of cancer, which has spread beyond the original site. Some of the advanced imaging techniques at Hoag include:
Back to Top
Treatment/Technology
Hoag Cancer Center’s expert medical team works together to determine the best course of treatment for each individual patient.
From minimally invasive surgical options, the latest in state-of-the-art radiation therapy and systemic therapy, Hoag’s comprehensive approach to prostate cancer has resulted in outstanding survival rates.
Surgery
Surgery is a vital component in the successful treatment of prostate cancer. Hoag Cancer Center medical team includes experienced surgeons and the latest techniques and technology in the surgical management of prostate cancer.
During 2007-2008 three Hoag-affiliated urologists, Drs. Bae, Freedman and Barme, performed the majority of prostatectomies.
Increasingly, prostatectomies are being performed via robot-assisted laparoscopy to minimize the extent of the surgery. Hoag surgeons utilize the
da Vinci® S HD™ Surgical System to perform robotic minimally invasive radical prostatectomy. Technological advantages, which include a high-definition optical magnification system and endo-wrist capability, afford a post-operative recovery during which patients experience less pain, less blood loss and quicker return to normal activities. Other potential benefits may include a faster return of urinary and sexual function.
Jeffrey Yoshida, M.D., a urologic oncologist, is an expert in robotic surgery and has performed more than 800 robotic prostatectomies prior to joining the Hoag Cancer Center team in April 2008.
To view an article with more information on robotic surgery at Hoag, click here. For more about tha da Vinci® S HD™ Surgical System, please click here.
Radiation Oncology
Radiation therapy is an alternative for the treatment of early prostate cancer, and is often used in the treatment of regionally advanced prostate cancer.
Hoag Cancer Center has an outstanding radiation oncology program. The entire first floor of the cancer center is dedicated to radiation oncology, where a highly specialized team of medical experts deliver the latest in state-of-the-art radiation therapy to patients. Hoag radiation oncologists are expert in the use of seed-implant brachytherapy. For patients with more advanced prostate cancer, and sometimes as an adjunct to surgery, image guided IMRT is available.
Hoag’s radiation oncology program offers a full spectrum of leading-edge radiation treatment options. For a complete list of radiation oncology services, please click here.
Systemic Therapy
Systemic therapy is an important component of care for those few patients who have advanced disease at diagnosis, and for patients who eventually progress to have metastatic disease.
Hoag is committed to providing the latest in systemic therapy options to patients with prostate cancer. Hoag has 35 board-certified medical oncologists on staff, each of whom are experts in the delivery of hormonal therapy and chemotherapy.
Treatment of Metastatic Disease
Although it is uncommon to detect metastatic prostate cancer at the time of diagnosis, many men eventually develop metastatic prostate cancer, typically in the bones.
Hormonal therapy is usually effective initially, and systemic chemotherapy is typically used in patients who develop hormone-refractory prostate cancer. Increasingly, local therapies are being used to eliminate certain sites of metastatic prostate cancer.
For patients with small numbers of metastases to the liver, surgical resection, radiofrequency ablation, cryoablation and tomotherapy are all treatment options, in addition to systemic therapy or intrahepatic chemotherapy.
Isolated lung metastases may be treated by surgical resection, preferably video-assisted thoracic surgery, radiofrequency ablation, cryoablation or radiation therapy.
Bone metastases are typically treated with radiation therapy, whereas brain metastases can usually be effectively treated by Gamma Knife.
With the availability of all these treatment options, the outlook for patients with metastatic cancer is more hopeful than ever.
Back to Top
Hereditary Cancer Program
Of the one in six American men who will develop prostate cancer in their lifetime, approximately five to 10 percent are in hereditary prostate cancer families.
Having a first degree relative (father, brother or son) with prostate cancer doubles a man’s risk to a one-in-three chance of developing prostate cancer. Men with two or more first degree relatives with prostate cancer likely have a prostate cancer risk greater than one in three.
With one exception (see below), at this time, genetic testing is not available on a commercial basis for hereditary prostate cancer. However, in families with multiple cases of prostate cancer in close relatives, referral can be made to organizations which are researching hereditary prostate cancer genes.
Prostate cancer is known to occur more frequently, at a younger age and possibly more aggressively, in male carriers of the hereditary breast/ovarian cancer (BRCA1 and BRCA2) genes. If prostate cancer occurs in a family where there is also early-onset breast cancer and/or ovarian cancer, then genetic testing of the family may be indicated.
For more information about hereditary cancer, click here or call Hoag’s Hereditary Cancer Program at 949/764-5764.
Back to Top
Multidisciplinary Urologic Oncology Cancer Case Conferences
Hoag’s multidisciplinary urologic oncology cancer case conferences provide collaborative care planning for prostate cancer patients.
This twice monthly cancer case conference brings together a multidisciplinary team of prostate cancer specialists, including urologists, medical oncologists, radiation oncologists, radiologists, pathologists, nurses and support staff.
Back to Top
Clinical Trials
Clinical trials are sometimes available for prostate cancer. To learn more about Hoag Cancer Center’s Clinical Trials Department, and the clinical trials currently available at Hoag, please click here.
Back to Top
Prostate Cancer Patient Education and Support
The Man to Man Prostate Cancer Discussion Group is held on the first Wednesday evening of each month, from 6:30-8 p.m. in Hoag Cancer Center Auditorium. Hoag physicians who specialize in the treatment of prostate cancer speak to the group on a different topic each month regarding treatment options or issues related to care. In addition to providing education, this forum provides patients and their families the opportunity to speak to other patients their experiences in treatment for prostate cancer.
Nancy Raymon, R.N., M.N., Urologic Cancer Nurse Coordinator, facilitates these monthly meetings.
Back to Top
Cancer Education
To learn more about prostate cancer, please visit the website of the National Cancer Institute.
Back to Top
Back to Top
--%>
|
|
|
|